Understanding the Limitations of BMI in Cardiovascular Risk Assessment
In recent discussions within the biopharmaceutical landscape, a new presentation from Theratechnologies has shed light on a critical issue impacting healthcare for individuals living with HIV. The company, known for its innovative approaches, emphasized that relying solely on body mass index (BMI) may not offer a comprehensive picture of cardiovascular (CV) risk in this diverse population.
During a notable presentation at a major conference on retroviruses and opportunistic infections, researchers from Theratechnologies explored how the traditional measures of BMI can obscure the true cardiovascular risks many individuals with HIV face. The heart of the findings revolves around the significance of assessing excess visceral abdominal fat (EVAF), a factor often overlooked in standard BMI evaluations.
The Insights from the VAMOS Study
The company's research stems from a detailed study named the Visceral Adiposity Measurement and Observation Study (VAMOS), which involved over 170 participants. This investigation focused on understanding how BMI correlates with the presence of visceral fat and overall cardiovascular health in patients who have achieved virological suppression on antiretroviral therapy (ART) for an extended period.
Researchers discovered that many individuals classified as having a normal or slightly overweight BMI exhibited dangerously high levels of EVAF, which could indicate a higher risk of cardiovascular disease. They found that approximately 43% of individuals with a normal BMI had EVAF, along with 47% of those categorized as overweight. Surprisingly, this included patients who were not traditionally considered at risk based on their BMI alone.
Key Statistical Findings
The study highlighted that individuals with high EVAF consistently showed elevated 10-year atherosclerotic cardiovascular disease (ASCVD) risk scores compared to those without EVAF, irrespective of their BMI status. This presents a compelling argument for healthcare professionals to advance their screening practices to better capture this risk factor, ensuring a more comprehensive approach to cardiovascular health in patients living with HIV.
The Need for a Transition in Screening Practices
The implications of the VAMOS study call for healthcare providers to reconsider their reliance on BMI as an isolated indicator of health, particularly when evaluating cardiovascular risk. While BMI has been a longstanding measure in clinical settings, it is clear that a multifaceted approach may yield better health outcomes.
As Dr. Karam C. Mounzer, the lead investigator, noted, the prevalence of obesity and weight gain in HIV patients is substantial. He urges clinicians to incorporate additional screening methods, such as measuring waist circumference, to better assess visceral fat.
Your Health and Cardiovascular Risk
Healthcare providers are encouraged to look beyond traditional metrics and prioritize the need to screen for EVAF among their patients. The impact of visceral fat on cardiovascular health cannot be overstated, and adjusting screening practices could lead to significant improvements in patient care.
About Theratechnologies
Theratechnologies, a prominent player in the biopharmaceutical industry, is dedicated to delivering innovative treatments that aim to redefine current standards of care. With a strong commitment to research and development, the company's focus remains on addressing unmet medical needs, particularly within vulnerable populations such as those affected by HIV.
To learn more about the advancements and innovative therapies offered by Theratechnologies, visit the company's official website for further details and updates regarding their ongoing research efforts and clinical studies.
Frequently Asked Questions
What does the VAMOS study reveal about BMI?
The VAMOS study reveals that BMI alone is insufficient for assessing cardiovascular risk in people with HIV, highlighting the need for additional metrics like EVAF.
Why is EVAF important in assessing cardiovascular risk?
EVAF is a significant indicator of cardiovascular health; it identifies individuals at risk who may not be flagged by BMI alone, particularly among those with normal BMI.
How can healthcare providers improve cardiovascular risk assessments?
Providers are encouraged to use comprehensive screenings, including waist circumference measurements, to better assess EVAF and overall cardiovascular risk.
What is the mission of Theratechnologies?
Theratechnologies aims to develop innovative therapies that redefine standards of care in therapeutic areas with high unmet needs and improve patient outcomes.
Where can I find more information about Theratechnologies?
For detailed information and updates about Theratechnologies, visit their official website or their pages on various financial regulatory platforms.
